
Corgi Genomics & Precision Medicine ETF (GNMX)
GNMXBATSCorgiEquity
As of Nov 20, 2026 close
- Assets (AUM)
- $2.80M
- Expense ratio
- 0.35%
- Dividend yield
- -
- Holdings
- 59
- 52-week range
- $23.88$39.86
- Volume (live)
- -
- Avg. volume (3M)
- 1.21K
GNMX ETF Holdings: Corgi Genomics & Precision Medicine ETF
The largest positions with their portfolio weights, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 25 of 59 GNMX Holdings by Portfolio Weight
Holdings data last updated Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position. Fund disclosures available to us list the largest 25 positions.
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 | ![]() | Thermo Fisher Scientific Inc | Stock | 8.45% |
| 2 | ![]() | Moderna, Inc. | Stock | 8.40% |
| 3 | ![]() | Vertex Pharmaceuticals Incorporated | Stock | 6.52% |
| 4 | ![]() | Illumina, Inc. | Stock | 4.70% |
| 5 | ![]() | 10x Genomics, Inc. | Stock | 3.85% |
| 6 | ![]() | Guardant Health, Inc. | Stock | 3.65% |
| 7 | ![]() | Revolution Medicines, Inc | Stock | 3.64% |
| 8 | ![]() | Twist Bioscience Corporation | Stock | 3.12% |
| 9 | ![]() | Iovance Biotherapeutics, Inc. | Stock | 3.10% |
| 10 | ![]() | Incyte Corporation | Stock | 2.95% |
| 11 | ![]() | Genmab A/S | Stock | 2.88% |
| 12 | ![]() | Alnylam Pharmaceuticals, Inc | Stock | 2.75% |
| 13 | MUTF:FGXXX | First American Government Obligs X | Stock | 2.56% |
| 14 | ![]() | Bio-Techne Corporation | Stock | 2.13% |
| 15 | ![]() | GRAIL, Inc. | Stock | 2.13% |
| 16 | ![]() | BioMarin Pharmaceutical Inc. | Stock | 1.97% |
| 17 | ![]() | Tempus AI, Inc. | Stock | 1.93% |
| 18 | ![]() | CareDx, Inc. | Stock | 1.92% |
| 19 | ![]() | Qiagen N.V. | Stock | 1.76% |
| 20 | ![]() | Krystal Biotech, Inc. | Stock | 1.74% |
| 21 | ![]() | Adaptive Biotechnologies Corporation | Stock | 1.73% |
| 22 | ![]() | Schrödinger, Inc. | Stock | 1.49% |
| 23 | ![]() | Arrowhead Pharmaceuticals, Inc. | Stock | 1.42% |
| 24 | ![]() | CRISPR Therapeutics AG | Stock | 1.40% |
| 25 | ![]() | NeoGenomics, Inc. | Stock | 1.39% |
Source: Fund holdings disclosures. Last updated Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About Corgi Genomics & Precision Medicine ETF Holdings
What are the top holdings in GNMX?
In holdings data last updated Oct 4, 2026, GNMX's largest holdings are Thermo Fisher Scientific Inc (TMO) at 8.45%, Moderna, Inc. (MRNA) at 8.40%, Vertex Pharmaceuticals Incorporated (VRTX) at 6.52%, Illumina, Inc. (ILMN) at 4.70% and 10x Genomics, Inc. (TXG) at 3.85%. Together these 5 positions make up 31.9% of the fund. GNMX holds 59 securities in all; the holdings data lists the top 25 by weight.
How concentrated is GNMX's portfolio?
In holdings data last updated Oct 4, 2026, the 10 largest of GNMX's 59 positions make up 48.4% of assets. The largest single position is Thermo Fisher Scientific Inc (TMO) at 8.45%. The top 25 listed positions add up to 77.6%, so the remaining 34 holdings share 22.4%. Its largest sector, Healthcare, is 100.0% of the portfolio.
What is GNMX's sector allocation?
In holdings data last updated Oct 4, 2026, GNMX's largest sector weights are Healthcare (100.0%), together 100.0% of the portfolio. It has exposure to 1 sector in total.
What countries does GNMX invest in?
In holdings data last updated Oct 4, 2026, 92.6% of GNMX's portfolio is invested in the United States, followed by Denmark (2.8%), Netherlands (2.6%) and Switzerland (2.0%). GNMX has exposure to 4 countries in total.























